In FDA dou­ble head­er, reg­u­la­tors al­so of­fer a green light to Rigel's fos­ta­ma­tinib

Fast on the heels of Ul­tragenyx’s big FDA win, Rigel $RIGL came through with an FDA ap­proval for fos­ta­ma­tinib, a new sec­ond-line ther­a­py for throm­bo­cy­tope­nia in adult pa­tients with chron­ic im­mune throm­bo­cy­tope­nia. The ther­a­py will be sold as Tavalisse.

The news spread fast on Twit­ter af­ter the FDA post­ed the la­bel for the drug, which ar­rived just days af­ter some­one at the com­pa­ny ac­ci­den­tal­ly post­ed a no­tice of the OK ahead of the of­fi­cial word.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.